Head-to-head · WeighScore
Bliv vs Queen RX
The verdict
Too close to call — both grade 66.3/100 (C).
Bliv and Queen RX land on the same WeighScore, so neither clears the other on our six graded dimensions. Bliv sits one line higher on the board (#187 vs #192) on the underlying tiebreak, but it's a genuine coin-flip — pick on the factors and prices that matter most to you below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Bliv | Queen RX |
|---|---|---|
| WeighScore | 66.3/100 | 66.3/100 |
| Grade | C | C |
| Scorecard rank | #187 | #192 |
| Semaglutide | $116/mo (as low as, varies by plan and eligibility, compounded) | $100/mo (quarterly plan, compounded) |
| Tirzepatide | $199/mo (as low as, varies by plan and eligibility, compounded) | Not disclosed |
| Coverage | Coverage not published | 45 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #187 · C
Strengths
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
Where it loses points
- The advertised rates are 'as low as' figures footnoted 'based on plan structure and eligibility', and the plan selector sits behind the medical intake — the rate you are offered is not knowable before you hand over a medical history
- A $24.99 provider consultation fee is charged on top, and the refund policy deducts $200 for 'clinical coordination and account setup'
- The homepage advertises 'no long-term commitments or cancellation fees' while the terms require the membership fee to be paid 'in a single sum', call it non-refundable and refer to a 'Membership Term'
- The only figure smaller than the advertised rate is a $29 CareCredit/Klarna instalment, which is a financing payment rather than the price of a month of medication
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #192 · C
Strengths
- $299/quarter (~$100/mo) — among the lowest GLP-1 pricing in the dataset
- Three GLP-1 options: semaglutide, tirzepatide, and liraglutide
- 45-state coverage
Where it loses points
- No LegitScript or PCAB accreditation
- No legal entity name or address disclosed
- No named pharmacy partners
- Not available in KS, LA, MS, NM, WV
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.